FDA Approves Phase 2 Trial for Promising New Drug AK3280 to Treat Pulmonary Fibrosis #Shanghai #United_States #FDA_Approval #AK3280 #Ark_Biopharmaceutical
1
0
0
0
FDA Approves Phase 2 Trial for Promising New Drug AK3280 to Treat Pulmonary Fibrosis #Shanghai #United_States #FDA_Approval #AK3280 #Ark_Biopharmaceutical
Ark Biopharmaceutical's Aizhida Approved in China for ADHD Treatment #China #Shanghai #ADHD #Ark_Biopharmaceutical #Aizhida
Ark Biopharmaceutical Gains Approval for Azstarys® to Treat ADHD in China #China #Shanghai #Azstarys #ADHD_treatment #Ark_Biopharmaceutical